Mitochondrion

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Glioblastoma, NSCLC, Diabetes, Lung, Lung cancer, Metabolism, EGFR, Osteosarcoma, MD, Neoplasm, FDA, Cancer, Glycolysis, Food, Growth, Anaplastic lymphoma kinase, Pembrolizumab, AACR, Cell, Apoptosis, Date, Osimertinib, Agonal respiration, Mitochondrion, Breast, University, Nanoparticle, Food and Drug Administration, NPRL2, Patient, ATP, Clinical trial, Gene, Disease, TUSC2, Trial of the century, Mesothelioma, Research, ALK, Vaccine

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Baszucki Group Announces Columbia University's Martin Picard, PhD as Inaugural Recipient of $1.5 Million Baszucki Prize in Science

Retrieved on: 
Tuesday, March 5, 2024
SAN, Metabolism, Mental health, Doctor of Philosophy, Neuroscience, Ageing, Overalls, Neurology, Behavioral medicine, Communication, Mitochondrion, Health, Genetics, Columbia, Associate, Teaching, Medicine, Disease, DSM-IV codes, Research, Brain, Pharmaceutical industry

SAN MATEO, Calif., March 5, 2024 /PRNewswire/ -- Baszucki Group today announced that Columbia University's Martin Picard, PhD, is the first to receive the new Baszucki Prize in Science. Dr. Picard, Associate Professor of Behavioral Medicine in Psychiatry and Neurology, received the $1.5 million prize for his groundbreaking work connecting brain energetics and mitochondria to the human experience. Dr. Picard has led seminal research establishing mitochondrial psychobiology as a critical new field advancing our understanding of health and disease.

Key Points: 
  • Dr. Picard has led seminal research establishing mitochondrial psychobiology as a critical new field advancing our understanding of health and disease.
  • "Baszucki Group has been an invaluable supporter of our work and I am honored to be the first to receive this prestigious new prize," said Dr. Picard.
  • Baszucki Group's prize programs are designed to reward progress in science, medicine, and other disciplines.
  • The newly established Baszucki Prize will periodically recognize an individual who has leveraged prior Baszucki Group funding to make exceptional contributions to their field.

Michael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer Research

Retrieved on: 
Wednesday, February 21, 2024
Stomach cancer, Neoplasm, De Gregorio, Doctor of Philosophy, MD, Immunotherapy, Esophageal cancer, Grant, Cancer, Mitochondrion, Associate, Patient, Protein, Baylor College of Medicine, Research, Mouse, Baylor University, Pharmaceutical industry

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Normally, the tumor cell 'energy center', called the mitochondria, protect the tumor cell from treatment with either chemotherapy or immunotherapy.
  • "The support of the DeGregorio Family Foundation is critical to the success of our research; we very much appreciate it," said Dr. Ripley.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $8 million to fund innovative research to cure gastric and esophageal cancers.

Juntendo University Broadens the Scope of Mitochondrial Disease Testing

Retrieved on: 
Monday, February 12, 2024
Mitochondrial disease, Pediatrics, Medical research, Juntendo University, Clinical Laboratory, Mitochondrion, Cardiomyopathy, Hearing loss, RNA, Adolescence, Adenosine, Genetic testing, ATP, Disease, Insurance, Kidney, Diagnosis, Development, Research, DNA, Seizure, Pharmaceutical industry

TOKYO, Feb. 12, 2024 /PRNewswire/ -- Mitochondrial disease occurs when malfunctioning mitochondria cannot sustain the production of adenosine triphosphate (ATP)—the energy currency of life—in the inner mitochondrial membrane. The loss of this vital molecule has far-reaching consequences that affect various organ systems and can cause psychiatric symptoms, cardiomyopathy, seizures, kidney and liver dysfunction, and hearing loss.

Key Points: 
  • The Intractable Disease Research Center at Juntendo University will conduct broader analyses of mitochondrial genetic data to confirm genetic diagnosis.
  • Unfortunately, mitochondrial disease is the most common congenital metabolic condition, with one case detected for every 5000 live births.
  • In terms of testing, Juntendo University screens many babies diagnosed with mitochondrial disease each year.
  • In this regard, Prof. Murayama's team commenced mitochondrial disease outpatient care at Juntendo Medical Center's Pediatric and Adolescent Department in July 2023.

Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle

Retrieved on: 
Thursday, February 8, 2024
Partnership, Mitophagy, CHF, Lead, European, Conditional sentence, Science, Research, Deficit spending, AP-HP, MD, Mitochondrion, Therapy, Myopathy, Lung, CNS, Dementia, NASH, Liver, Pharmaceutical industry

Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.

Key Points: 
  • Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.
  • Innosuisse is the Swiss Innovation Agency that helps to fund science-based pre-commercial projects of start-ups with significant innovation potential.
  • Klaus Dugi, MD, CEO of Vandria, said, “These prestigious grant awards are an endorsement of the science and the team behind Vandria.
  • The Eurostars grant significantly helps us to advance, in parallel, our program in muscle disease.

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Retrieved on: 
Wednesday, February 7, 2024
Transfer, AACR, TUSC2, Toxicity, Survival, Cell, Research, NSCLC, DNA, NPRL2, Mitochondrion, Lung cancer, Gene, Patient, FDA, ALK, Mouse, Food, Crizotinib, Diabetes, Risk, Biology, Metabolism, Meharry Medical College, Cancer, University, Malignancy, Vaccine

AUSTIN, Texas, Feb. 7, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.

Key Points: 
  • The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.
  • "Research indicates that the TUSC2 gene used in REQORSA may benefit many types of cancers and potentially the treatment of other diseases.
  • Research collaborators at the Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative are studying the combination of Genprex's REQORSA, which uses the TUSC2 tumor suppressor gene, with various ALK inhibitors.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.

Why do people and animals need to breathe? A biologist explains why you need a constant source of oxygen

Retrieved on: 
Tuesday, February 6, 2024
Plant, Capillary, Oxygen, Photosynthesis, Cell, Human, Bacteria, Gestational sac, Mitochondrion, Learning, Food, Nitrogen, Soil, Carbon, Atmosphere, Nutrient, Animal, Skin, Eating, Water, Protein, Stomach, Biology, Gill, Rest, Blood, Kid, Toy

But to turn it into energy, they need one more ingredient – oxygen.

Key Points: 
  • But to turn it into energy, they need one more ingredient – oxygen.
  • All living things need oxygen, except for some bacteria and a few tiny animals that don’t.
  • Because you need a lot of oxygen, your lungs need a lot of surface area to do their job.
  • That means you need to take five breaths just to get the equivalent of one complete lungful of oxygen.

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Retrieved on: 
Sunday, February 4, 2024
Hearing, Inflammation, Civil service commission, Knowledge, European, Cell, Haematopoiesis, COMP, IRIS, Bone marrow, Mitochondrion, Adrenal insufficiency, Regulation, Gland, ABCD1, Patient, Safety, Diagnosis, EMA, ALD, European Commission, Adrenoleukodystrophy, Seizure, B cell, PPAR, Brain, Disease, Therapy, Eurostat, Tissue, Dementia, Medicine, Committee, Hormone, DSM-IV codes, Spinal cord, Pharmaceutical industry

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Key Points: 


Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Wellness Redefined: Return Healthy Launches Unique Approach to Enhancing Physical, Mental, and Emotional Resilience

Retrieved on: 
Thursday, January 25, 2024
Collection, Dicarboxylic acid, Liver, Philosophy, Mineral, Symmetry, Mitochondrion, Vitamin, Health, Cell, Immune system

With safe, effective ingredients that focus on nourishing the mind, body, and spirit, Return Healthy is dedicated to providing the right building blocks for robust cell membranes and energetic mitochondria—the powerhouses of cells.

Key Points: 
  • With safe, effective ingredients that focus on nourishing the mind, body, and spirit, Return Healthy is dedicated to providing the right building blocks for robust cell membranes and energetic mitochondria—the powerhouses of cells.
  • Return Healthy’s CEO, Dr. Werner Vosloo, ND, said, “We understand that nourishing the mind, body, and spirit is not a luxury but a necessity in our fast-paced, nutrient-depleted world.
  • These include:
    Adaptogen Immune: A botanical marvel, Adaptogen Immune blends adaptogens and immune-modulating herbs, offering support against post-stress burnout and enhancing overall resilience.
  • The website encourages those interested in taking a unique approach to their health, wellness, and vitality to browse its range of high-quality supplements or reach out to its friendly customer service team today via its online contact form.

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

Retrieved on: 
Tuesday, January 23, 2024
Patient, Regenerative medicine, Fertility, Paratriathlon, AAV, Intercept Pharmaceuticals, Kite Pharma, University, Mitochondrion, Term sheet, LHON, Shearson, Acquisition, Safety, Vice, Intellectual property, FDA, Capsid, Letter, Arsenic trioxide, Paramount, Pharmaceutical industry

“The NAYA leadership team brings an agile entrepreneurial platform, broad development and commercialization experience, and access to public capital, which will unlock the potential of our promising AAV gene therapy platform for mitochondrial genetic diseases.

Key Points: 
  • “The NAYA leadership team brings an agile entrepreneurial platform, broad development and commercialization experience, and access to public capital, which will unlock the potential of our promising AAV gene therapy platform for mitochondrial genetic diseases.
  • The program has received over $6 million in grant funding to date and qualifies for Regenerative Medicine Advanced Therapy (RMAT) designation and multiple priority FDA review vouchers.
  • The combination of multiple orphan indications, multiple routes of administration, and multiple AAV serotypes applicable supports a broad gene therapy platform for mitochondrial orphan diseases.
  • The Florida Biotechnologies Transaction is contingent on the closing of the INVO Merger and sufficient financing to further develop the gene therapy programs from Florida Biotechnologies.